These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor-positive, HER2-negative early-stage invasive breast cancer.

The goal of this activity is to improve participants' knowledge of, confidence in, and competence in integrating PARP inhibitors into treatment of patients with breast cancer.

The goal of this activity is to improve participants' knowledge of, confidence in, and competence in integrating PARP inhibitors into treatment of patients with breast cancer.

NCCN is pleased to host this webinar on the topic of "Barriers to the Coordination of Cancer Care" in the NCCN 2018 Congress Series: Breast Cancer with Updates from the 2017 San Antonio Breast Cancer Symposium (SABCS).

NCCN is pleased to welcome Harold J.

NCCN is pleased to welcome William J. Gradishar, MD from Robert H.

NCCN is pleased to welcome Therese B.

This information was originally presented at the NCCN 23rd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care held in Orlando, Florida, from March 22 - 24, 2018.